IceCure Is Down 90% While the Commercial Machine Turns. The H1 Report Could Prove It.

The market is pricing IceCure Medical like a company waiting for the other shoe to drop. The stock has fallen nearly 90% over the past year. It trades at a $10.7 million market cap with an enterprise value of just $2.75 million. That's net of $8.1 million in cash and almost no debt. At a $2.75 million valuation, the market is effectively assigning zero value to the business itself - as if tomorrow is the last day.

But the operating setup behind that price tells a different story for the next 12 months.

IceCure's ProSense cryoablation system received FDA marketing authorization in October 2025 for the local treatment of low-risk, early-stage breast cancer in women aged 70 and above. Since then, the commercial numbers have been moving in one direction. First-quarter revenue rose 26% year-over-year to $911,000. North American sales jumped 84%. The active U.S. install base grew 70% following FDA clearance. And on June 17, the company announced that growth explicitly - procedures are now running in major markets across the country, from Los Angeles to New York to Atlanta to Dallas.

The market has not moved. The stock sits at roughly $3.13, below its 200-day moving average of $13.87. Short interest has come down from the spring, to 3.25% of shares outstanding. Nobody's rushing in. But the tape pain and the business pain are no longer the same thing.

The proof point: install base plus reimbursement

Here's what matters most. Cryoablation for breast cancer is a minimally invasive alternative to surgery - it freezes tumors rather than cutting them out. It's done in an office or CT room, not an operating theater. The recovery is faster. The risk profile is lower for elderly patients who might otherwise avoid surgery.

What's changed since October is that physicians can now do it with confidence in the U.S. market. Before FDA clearance, hospitals could install the system but weren't using it aggressively. IceCure went from 13 active accounts to 19 in Q1 alone, a 46% jump. By mid-June, the total active U.S. commercial install base was up 70%.

Each active site sells disposable probes - the consumables used in every procedure - which means recurring revenue follows the install base. And the reimbursement framework already exists. The procedure is covered under a CPT Category III code that generates approximately $4,000 in facility fees. That's not new; it's just being used more now that clearance exists.

Two catalysts that compound the install story

The ChoICE post-marketing study adds structure to the commercial ramp. The FDA approved the study design in March 2026, and IceCure kicked off enrollment at its first U.S. site - the West Cancer Center in Tennessee - on July 27. The study will run across 30 clinical sites, enrolling up to 400 patients over 36 months. Under the approved design, each site is both a clinical study center and an active commercial installation. They treat enrolled patients while also offering the procedure to eligible patients outside the study. The study doesn't just generate data; it plants 30 active revenue-generating systems across the country that wouldn't exist otherwise.

Then there's the NCCN angle. On July 29, the Society of Interventional Oncology submitted a formal petition to the NCCN Breast Cancer Guidelines Panel asking for cryoablation to be included as a Category 2B recommendation for carefully selected patients. The American Society of Breast Surgeons already updated its resource guide in March 2026. NCCN inclusion would be a significantly broader stamp of recognition - the NCCN guidelines are among the most influential evidence-based recommendations in U.S. cancer care and are frequently referenced by clinicians, institutions, and payers. The petition isn't a done deal, but the momentum is directional.

The cash problem

This is where the old story still has weight. IceCure burned $14.89 million in free cash flow over the last 12 months. It has $8.12 million in cash. At the current burn rate, runway is measured in months, not years. The company filed an F-3 shelf registration in June covering 5.5 million additional shares - that's more than the 3.43 million currently outstanding. Dilution is a near certainty, not a possibility.

But dilution at a $2.75 million enterprise value is different from dilution at a $50 million enterprise value. When the operating multiple is near zero, the company is raising at a depressed price. Once the revenue inflection is visible, the next round of capital - or the market's recognition of the trajectory - looks materially better. The question isn't whether dilution comes. It's whether the revenue curve justifies what comes after.

What the H1 report has to show

The half-year results drop on August 12, before market open. Q1 revenue was $911,000. If Q2 continues the pattern of accelerating installs and procedure volume, H1 revenue should be meaningfully ahead of the $1.4 million run rate from the prior year. The proof isn't profitability - that's not the inflection point. The proof is whether revenue growth is steep enough to show the curve has bent.

The company has been signaling aggressively since May. CEO Eyal Shamir talked about a "strong pipeline" converting to revenue, plans to expand the U.S. sales footprint to eight regions, and an account that bought a second system for a new site at one of the largest healthcare systems in the country. The ChoICE first site went live in July. Brazil's interventional oncology market is expanding independently, with an ongoing 750-patient study there. The activity is real.

The setup

The market is still pricing the old story: a cash-burning medtech with tiny revenue and a 90% decline. The operating numbers are already pointing to something different - a post-approval commercial ramp with 70% install-base growth, a reimbursement framework in place, 30 hybrid clinical-commercial sites being established through the ChoICE study, and guideline momentum building from two professional societies.

Simple math on the valuation side. At $2.75 million enterprise value and a $3.57 million TTM revenue, the EV/sales multiple is roughly 0.8x. Even small-cap medtech companies trading on early revenue rarely go below 2x. If H1 revenue shows growth consistent with the install-base expansion and the company extends its cash runway, a rerating to even a modest 2x EV/sales implies more than triple the current enterprise value. That doesn't require profitability. It requires the market to stop pricing the company at zero.

What breaks it

The H1 report fails to show any meaningful revenue acceleration and management signals a need to raise capital imminently at a price that confirms the business isn't growing. Or dilution happens faster than revenue ramps, pushing the per-share value down further and resetting the timeline.

But right now, the worst case is already reflected in the $2.75 million enterprise value. The inflection case - revenue growth that finally justifies a normal multiple - is the one that hasn't been priced in yet.

Discipline over ego. The dilution risk is real. But the setup is a business with 70% install-base growth, zero debt, a net cash position, and an EV/sales multiple near 0.8x, about to report half-year results that could show the curve has bent. If the numbers continue to improve, the market has no reason to keep pricing this at zero.